A Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effect of Exogenous Melatonin on Delayed Sleep Phase Syndrome
Leonid Kayumov, PhD, ABSM,
Gregory Brown, MD, PhD,
Ripu Jindal, MD,
Kenneth Buttoo, MD, ABSM and
Colin M. Shapiro, MD, PhD
From the Department of Psychiatry, University of Toronto, and Sleep Research Laboratory, University Health Network, Toronto Western Hospital (L.K., G. B., R.J., C.M.S.); Toronto Western Research Institute, University of Toronto (L.K., C.M.S.); and Ajax-Pickering General Hospital (K.B.), Pickering, Ontario, Canada.
View larger version (17K):
[in a new window]
|
Fig. 2. aMT6s excretion in relation to time of day. The typical nocturnal rise is shown.
|
|
View larger version (18K):
[in a new window]
|
Fig. 3. aMT6s excretion in a subset of five patients with DSPS. An abnormal peak during the initial half of daytime is shown.
|
|
View larger version (29K):
[in a new window]
|
Fig. 4. Normalization of aMT6s excretion in patients with DSPS treated with exogenous melatonin. Note the low levels of aMT6s during the initial half of daytime (cf, Figure 3).
|
|
Copyright © 2001 by the American Psychosomatic Society
